Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.73 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | TLR2 | O60603 | 1/20 | 0.47 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.47 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL793384 | 0.89 | KMT2A (0.85) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL2906210 | 0.89 | KMT2A (0.68) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL1247484 | 0.88 | KMT2A (0.71) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL35211560 | 0.88 | KMT2A (0.70) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL8815097 | 0.88 | KMT2A (0.70) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL30353304 | 0.87 | KMT2A (0.70) | KMT2AEPHX2TLR2TLR1FABP7 | |
| SCHEMBL30823950 | 0.86 | KMT2A (0.61) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL8049533 | 0.86 | KMT2A (0.79) | KMT2AEPHX2TLR2TLR1CASP3 | |
| SCHEMBL29482640 | 0.86 | KMT2A (0.97) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL97174 | 0.86 | KMT2A (0.97) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2024-03-14 | — | — | US | disclosed |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2022-06-23 | — | — | US | disclosed |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2020-01-23 | — | — | US | disclosed |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS (US) | 2019-01-31 | — | — | US | disclosed |
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2018-07-26 | — | — | US | disclosed |
| US-9957246-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ZYNERBA PHARMACEUTICALS, INC. (US) | 2018-05-01 | — | — | US | disclosed |
| US-20170088533-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. | 2017-03-30 | — | — | US | disclosed |
| EP-2963031-A2 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | Zynerba Pharmaceuticals, Inc. (US) | 2016-01-06 | — | — | EP | disclosed |
| US-20150218121-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-08-06 | — | — | US | disclosed |
| EP-2215071-B1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ZYNERBA PHARMACEUTICALS INC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-8980942-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ZYNERBA PHARMACEUTICALS, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-20120289484-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. | 2012-11-15 | — | — | US | disclosed |
| US-8227627-B2 | Prodrugs of tetrahydrocannabinol, compositions comprising prodrugs of tetrahydrocannabinol and methods of using the same | ALLTRANZ INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2215071-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | AllTranz Inc. (US) | 2010-08-11 | — | — | EP | disclosed |
| WO-2009073633-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | ALLTRANZ INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | ALLTRANZ (US) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180208572-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20120289484-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20200247774-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20190233387-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20200024248-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20150218121-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20240083866-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1832/4885EPHX2 118/4885TLR2 2924/4885 |
| US-20090143462-A1 | Products of Tetrahydrocannabinol, Compositions Comprising Prodrugs of Tetrahydrocannabinol and Methods of Using the Same | CNR2, CNR1, FAAH | KMT2A 1787/4885EPHX2 121/4885TLR2 2959/4885 |
| US-20220194916-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20190031637-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20170088533-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20210047284-A1 | PRODRUGS OF TETRAHYDROCANNABINOL, COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1714/4885EPHX2 130/4885TLR2 2467/4885 |
| US-20240217942-A1 | PRODRUGS OF TETRAHYDROCANNABINOL COMPOSITIONS COMPRISING PRODRUGS OF TETRAHYDROCANNABINOL AND METHODS OF USING THE SAME | CNR2, CNR1, FAAH | KMT2A 1832/4885EPHX2 118/4885TLR2 2924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.